Therapeutic Solutions International Releases "DermalStilbene" a Topical Formulation of Pterostilbene
May 21 2018 - 9:00AM
InvestorsHub NewsWire
Therapeutic Solutions
International Releases
"DermalStilbene"
a Topical Formulation of Pterostilbene
Oceanside, CA
-- May
21, 2018
--
InvestorsHub NewsWire -- Therapeutics
Solutions International, Inc., (OTC
Markets:
TSOI) announced
today the availability of a
topical form of pterostilbene called "DermalStilbene."
As previously stated,
pterostilbene has been demonstrated in numerous publications to
possess therapeutic effects in animal models of numerous
inflammatory-associated conditions including cancer, diabetes, and
heart failure, but it has also been shown to "protect
hairless
mice against UVB radiation-induced skin damage and
carcinogenesis1", and
"was able to reduce
biofilm formation and kill the MRSA in immune cells by virtue of
its strong antibacterial activity and facile delivery across
biomembranes2"
"The
release
of this new product is meant to complement our other pterostilbene
containing products such as ProJuvenol and NanoStilbene, and we are
pleased to make this available to our customers for topical
application," said Timothy
Dixon, President, and CEO of Therapeutic Solutions
International.
"Pterostilbene is a
more potent form of resveratrol, which both activate similar
molecular pathways including SIRT-1. This protein called a
"sirtuin"
is known to possess anti-aging effects based on laboratory
studies3. While clinical
studies have not been performed yet, it is not outside of the realm
of possibility that pterostilbene based products may possess a
beneficial effect on aging cells" said
Dr. James
Veltmeyer, Republican Congressional Candidate and Scientific
Advisory Board Member of TSOI.
1
https://www.sciencedirect.com/science/article/pii/S0891584915001513
2
https://www.frontiersin.org/articles/10.3389/fmicb.2017.01103/full
3
https://www.ncbi.nlm.nih.gov/pubmed/28587197
About Therapeutic Solutions International,
Inc.
Therapeutic Solutions
International is focused on immune modulation for the treatment of
several specific diseases. Immune modulation refers to the ability
to upregulate (make more active) or downregulate (make less active)
one's immune system. The Company's corporate website is
www.therapeuticsolutionsint.com
and
e-commerce at www.youcanordernow.com.
Safe Harbor
Statement
This release contains
forward-looking statements that are based upon current expectations
or beliefs, as well as a number of assumptions about future events.
Although we believe that the expectations reflected in the
forward-looking statements and the assumptions upon which they are
based are reasonable, we can give no assurance that such
expectations and assumptions will prove to have been correct.
Forward-looking statements are generally identifiable by the use of
words like "may," "will," "should," "could," "expect,"
"anticipate," "estimate," "believe," "intend," or "project" or the
negative of these words or other variations on these words or
comparable terminology. The reader is cautioned not to put undue
reliance on these forward-looking statements, as these statements
are subject to numerous risk factors as set forth in our SEC
filings. To the extent that statements in this press release are
not strictly historical, including statements as to product launch
timing, revenue projections, business strategy, outlook,
objectives, future milestones, plans, intentions, goals, future
collaboration agreements, or otherwise as to future events, such
statements are forward-looking, and are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. The forward-looking statements contained in this release
are subject to certain risks and uncertainties that could cause
actual results to differ materially from the statements
made.
CONTACT
INFORMATION
Therapeutic Solutions (PK) (USOTC:TSOI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Therapeutic Solutions (PK) (USOTC:TSOI)
Historical Stock Chart
From Sep 2023 to Sep 2024